arrow
R

Ruixuan Jiang

merck sharp & dohme llc
H指数:15
被引数:1,333

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Real-world treatment patterns in stage III and IV melanoma patients: insights from a global multi-center chart review study
2026-07-250
OA
Number needed to treat (NNT) with pembrolizumab as an adjuvant therapy in resected patients with high-risk stage II (IIB and IIC) melanoma and its application to cost of preventing an event (COPE) in Mexico

以帕博利珠单抗作为辅助疗法,治疗高风险II期(IIB和IIC)黑色素瘤切除术后患者的需要治疗人数(NNT)及其在墨西哥预防事件成本(COPE)中的应用

2025-03-130
OA
Adjuvant pembrolizumab versus placebo in resected high- risk stage II melanoma: Health-related quality of life from the randomized phase 3 KEYNOTE-716 study

帕博利珠单抗与安慰剂在切除的高风险II期黑色素瘤中的辅助治疗: 来自随机3期KEYNOTE-716研究的健康相关生活质量

2022-11-0112
OAAI